AC Immune names new chief medical officer

26 July 2023

Swiss clinical-stage biotech AC Immune (Nasdaq: ACIU) today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist.

Dr Mendonça will join the company on October 1, and will also be appointed to the executive committee. He will replace current CMO Dr Johannes Streffer, who will leave the company at the end of September to pursue a new role.

Dr Mendonça was most recently the senior vice president, CMO, at Portugal’s largest drugmaker BIAL, where he led early and late-stage development programs across neuroscience and orphan diseases. He has further managed medical affairs and clinical operations in North America and Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK